EGFR and non-small cell lung carcinoma: The extended benefit of the sequential administration of a first-generation EGFR TKI followed by osimertinib observed in this study led to the approval of this compound for patients with NSCLC harboring T790M mutation and experiencing disease progression after first-generation or second-generation EGFR TKIs.